Table 3.
LR-Subjects (6) | HR-Subjects (5) | ||||||
---|---|---|---|---|---|---|---|
Before cART | Post cART | pW | Before cART | Post cART | pW | pM-W | |
% total-MDSCs | 0.3 [0.1–0.6] | 0.1 [0.1–0-4] | 0.3 | 0.1 [0.0–0.1] | 0.2 [0.0–0.2] | 0.043 | 0.9 |
% m-MDSCs | 0.3 [0.1–0.4] | 0.1 [0.1–0.3] | 0.3 | 0.1 [0.0–0.2] | 0.1 [0.0–0.2] | 0.5 | 0.9 |
% CCR2+ MDSCs* | 30.6 [16.4–40.4] | 48.1 [27.5–58.8] | 0.046 | 25.1 [23.9–25.1] | 50.3 [40.7–50.3] | 0.109 | 0.9 |
% β7+ MDSCs* | 60.4 [26.0–72.2] | 45.6 [19.5–69.2] | 0.6 | 14.8 [10.3–14.8] | 9.4 [8.5–9.4] | 0.109 | 0.5 |
% IDO+ MDSCs* | 2.0 [0.0–28.9] | 3.0 [0.6–7.8] | 0.5 | 3.4 [0.0–3.4] | 4.1 [0.0–4.1] | 0.180 | 0.8 |
% PDL1+ MDSCs* | 42.5 [28.7–62.7] | 32.5 [19.6–65.6] | 0.5 | 16.6 [9.2–16.6] | 22.8 [8.9–22.8] | 0.9 | 0.3 |
Variables are expressed as median and interquartile range [IQR]. pW, Wilcoxon rank test was used for longitudinal comparisons. pM-W, Mann–Whitney U test was used for transversal comparisons of post cART data. *The expression of functional molecules was determined in nine subjects (LR = 6 and HR = 3).
Statistically significant values are highlighted in bold, p < 0.005.